Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-12-18 00:00:00 ET · period of report 2024-12-16 · accession 0001883850-24-000061 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-18 | 2024-12-16 | REGN | Fenimore Christopher R. | CFO, SVP Fin | F - Tax | $730.81 | -491 | 16.3K | -3% | -$358.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-16 | F | D | 491 | $730.81 | 16,265 | D | — | — |